Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDC25A | P30304 | 4/20 | 0.65 |
| ▸ | POLA1 | P09884 | 1/20 | 0.65 |
| ▸ | ST6GAL1 | P15907 | 1/20 | 0.64 |
| ▸ | VDR | P11473 | 2/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.60 |
| ▸ | INPP5D | Q92835 | 1/20 | 0.60 |
| ▸ | FGF1 | P05230 | 7/20 | 0.57 |
| ▸ | HPSE | Q9Y251 | 7/20 | 0.57 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.56 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.56 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.56 |
| ▸ | FGF2 | P09038 | 6/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13347854 | 0.90 | VDR (0.76) | CDC25APOLA1ST6GAL1VDRCYP2D6 | |
| SCHEMBL13311422 | 0.90 | VDR (0.76) | CDC25APOLA1ST6GAL1VDRCYP2D6 | |
| SCHEMBL17124639 | 0.90 | VDR (0.76) | CDC25APOLA1ST6GAL1VDRCYP2D6 | |
| SCHEMBL18197739 | 0.90 | CDC25A (0.61) | CDC25APOLA1ST6GAL1VDRCYP2D6 | |
| SCHEMBL18195963 | 0.90 | CDC25A (0.61) | CDC25APOLA1ST6GAL1VDRCYP2D6 | |
| SCHEMBL25063600 | 0.87 | ABCC4 (0.78) | CDC25APOLA1ST6GAL1VDRCYP2D6 | |
| SCHEMBL8902867 | 0.87 | ABCC4 (0.78) | CDC25APOLA1ST6GAL1VDRCYP2D6 | |
| SCHEMBL8902302 | 0.87 | ST6GAL1 (0.82) | CDC25APOLA1ST6GAL1VDRCYP2D6 | |
| SCHEMBL8902307 | 0.87 | ST6GAL1 (0.82) | CDC25APOLA1ST6GAL1VDRCYP2D6 | |
| SCHEMBL23594716 | 0.87 | ABCC4 (0.78) | CDC25APOLA1ST6GAL1VDRCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9703193-B2 | Onium salt, resist composition, and patterning process | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2017-07-11 | — | — | US | disclosed |
| US-20160320698-A1 | ONIUM SALT, RESIST COMPOSITION, AND PATTERNING PROCESS | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 2016-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160320698-A1 | ONIUM SALT, RESIST COMPOSITION, AND PATTERNING PROCESS | SLC6A5, EIF2B5, EIF2B4 | CDC25A 2127/4885POLA1 1334/4885ST6GAL1 4522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.